These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28378734)

  • 21. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension.
    Martynyuk TV; Nakonechnikov SN; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):72-80. PubMed ID: 30701878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
    Dhillon S
    Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
    You R; Qian X; Tang W; Xie T; Zeng F; Chen J; Zhang Y; Liu J
    Can Respir J; 2018; 2018():1015239. PubMed ID: 30581511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.
    Chazova IE; Arkhipova OA; Martynyuk TV
    Ter Arkh; 2019 Mar; 91(1):24-31. PubMed ID: 31090367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.
    Wlodarczyk JH; Cleland LG; Keogh AM; McNeil KD; Perl K; Weintraub RG; Williams TJ
    Pharmacoeconomics; 2006; 24(9):903-15. PubMed ID: 16942124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macitentan for the treatment of pulmonary arterial hypertension.
    Sood N
    Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).
    Aldalaan AM; Saleemi SA; Weheba I; Abdelsayed A; Aleid MM; Alzubi F; Zaytoun H; Alharbi N
    Pulm Circ; 2022 Apr; 12(2):e12083. PubMed ID: 35514768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.
    Lilyasari O; Subekti Y; Atika N; Dinarti LK; Putri S; Opitasari C; Anggraini AB; Bussabawalai T; Teerawattananon Y
    BMC Health Serv Res; 2019 Aug; 19(1):573. PubMed ID: 31412857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.